List of Excipients in Branded Drug GEFITINIB

« Back to Dashboard

Generic Drugs Containing GEFITINIB

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	gefitinib	0480-4053	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals Inc	gefitinib	0480-4053	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals Inc	gefitinib	0480-4053	FERRIC OXIDE RED
Teva Pharmaceuticals Inc	gefitinib	0480-4053	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in GEFITINIB?

# Of NDCs	Excipient
3	CELLULOSE, MICROCRYSTALLINE
4	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE
1	DIMETHYLAMINOETHYL METHACRYLATE - BUTYL METHACRYLATE - METHYL METHACRYLATE COPOLYMER

Gefitinib Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Gefitinib is a mature, orally administered EGFR tyrosine kinase inhibitor with an established tablet formulation, broad generic availability outside the United States, and limited remaining composition-of-matter protection. The strongest commercial opportunities are in low-cost generic tablets, differentiated immediate-release formulations, pediatric or dysphagia-friendly presentations, regional regulatory filings, and manufacturing platforms that improve dissolution consistency without changing the active pharmaceutical ingredient.

Gefitinib excipient selection is constrained by its pH-dependent solubility, low aqueous solubility, high permeability, and the need to reproduce the reference product’s dissolution profile. Formulators should prioritize Q1/Q2 similarity where commercially practical, then use dissolution optimization, coating efficiency, and supply-chain control to create value.

What is gefitinib and how is it regulated?

Gefitinib is a small-molecule EGFR inhibitor marketed originally as Iressa by AstraZeneca. It is indicated for patients with metastatic non-small-cell lung cancer whose tumors have activating EGFR mutations, subject to jurisdiction-specific labeling and diagnostic requirements.

Regulatory item	Key information
Active ingredient	Gefitinib
Reference product	Iressa
Dosage form	Immediate-release film-coated tablet
Reference strength	250 mg
Original U.S. approval	Accelerated approval in 2003
U.S. regulatory status	Reapproved with mutation-directed labeling in 2015
U.S. NDA	021399
Companion diagnostic	FDA-approved EGFR mutation testing is relevant to patient selection
Biosimilar pathway	Not applicable; gefitinib is a chemically synthesized small molecule
Main regulatory routes	ANDA, 505(b)(2), national generic pathways, hybrid applications in Europe

The FDA initially approved Iressa under the accelerated approval pathway in May 2003. The product was later withdrawn from broad U.S. distribution after confirmatory-study concerns, then received renewed approval in July 2015 for patients with metastatic NSCLC carrying specific EGFR mutations (FDA, 2015).

The U.S. reference product is a 250 mg tablet administered once daily. Gefitinib is also marketed in multiple countries through generic and branded-generic products.

What excipients are used in the reference gefitinib tablet?

The U.S. Iressa label identifies a conventional tablet platform containing a filler, disintegrant, binder, lubricant, surfactant, and film-coating materials. The listed inactive ingredients include lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate, hypromellose, macrogol, titanium dioxide, and iron oxide-based colorants, subject to regional labeling differences (AstraZeneca, 2015).

Functional role	Reference excipient class	Formulation purpose
Diluent	Lactose monohydrate	Tablet mass and compressibility
Secondary diluent	Microcrystalline cellulose	Compactability and tablet strength
Disintegrant	Croscarmellose sodium	Rapid tablet breakup
Binder	Povidone	Granule or compact strength
Wetting aid	Sodium lauryl sulfate	Improved wetting of hydrophobic drug particles
Lubricant	Magnesium stearate	Ejection and tooling protection
Film former	Hypromellose	Mechanical protection and swallowability
Plasticizer or coating aid	Macrogol	Coating flexibility
Opacifier	Titanium dioxide	Appearance and light protection
Colorant	Iron oxide	Product identification

The formulation is commercially conservative. It does not depend on a lipid system, amorphous solid dispersion, cyclodextrin, or modified-release technology. That creates a relatively accessible generic-development pathway, but it also means that tablet disintegration and dissolution must be controlled tightly to avoid bioequivalence risk.

How does gefitinib solubility affect excipient selection?

Gefitinib is a weakly basic, poorly water-soluble compound with pH-dependent dissolution. Solubility is generally higher under acidic conditions and lower as pH increases. The drug’s permeability is sufficient for oral absorption, but dissolution can become the performance-limiting step.

The central excipient objectives are:

1. Improve wetting of the drug particles.
2. Promote rapid tablet breakup.
3. Avoid excessive hydrophobicity from over-lubrication.
4. Maintain consistent dissolution across pH conditions.
5. Prevent physical changes during storage.
6. Preserve tablet hardness without delaying disintegration.

Sodium lauryl sulfate is strategically important because it can improve wetting and dispersion of hydrophobic gefitinib particles. It must be controlled carefully because excessive surfactant can affect powder flow, tablet robustness, gastrointestinal tolerability, and dissolution behavior.

Croscarmellose sodium provides rapid swelling and wicking. Crospovidone is a potential alternative, but replacing the reference disintegrant can change the dissolution curve. A generic developer should evaluate both disintegrant identity and level rather than relying only on total disintegration time.

Microcrystalline cellulose and lactose provide a well-understood compression platform. Mannitol, dibasic calcium phosphate, spray-dried lactose, and starch-based fillers may support differentiated products, but each substitution creates additional comparative dissolution and stability work.

What formulation strategies are available for generic gefitinib?

Q1/Q2-matched immediate-release tablets

The lowest-risk approach is to reproduce the reference product’s qualitative and quantitative excipient composition as closely as feasible. This strategy can simplify formulation development and reduce the probability of unexpected dissolution behavior.

Commercial advantages include:

• Established manufacturing technology.
• Familiar excipient supply chains.
• Straightforward tablet compression.
• Lower formulation-development cost.
• Easier justification of excipient function in an ANDA.

The main disadvantage is limited product differentiation. Price, supply reliability, regulatory execution, and geographic coverage become the primary competitive levers.

Alternative wetting systems

A developer may replace sodium lauryl sulfate with another surfactant or use a lower surfactant concentration with improved API particle engineering. Candidate approaches include poloxamers, polysorbates, sodium stearyl fumarate combinations, or co-processed excipients.

This strategy has value when sodium lauryl sulfate creates tolerability, taste, or manufacturing problems. It carries a higher risk of dissolution divergence and may require more extensive formulation justification.

Direct-compression platforms

Direct compression can reduce processing steps and manufacturing cost. A platform using microcrystalline cellulose, spray-dried lactose, crospovidone, and a controlled lubricant level may be suitable if the API has acceptable flow and compressibility.

Direct compression is attractive for contract manufacturing and regional generic supply because it reduces solvent handling and drying capacity requirements. The main technical risks are content uniformity, segregation, capping, and sensitivity to lubricant mixing time.

Wet granulation

Wet granulation may improve content uniformity and tablet strength, especially where the API has poor flow. It can also improve the distribution of low-dose excipients such as surfactants.

The process introduces additional risks:

• API migration during drying.
• Moisture-related degradation.
• Longer cycle times.
• Solvent or water control.
• Scale-up variability.

Aqueous granulation should be evaluated against API solid-state stability and residual-moisture limits.

Solubility-enhanced formulations

Amorphous dispersions, hot-melt systems, spray drying, nanocrystals, and cyclodextrin complexes could improve dissolution. These technologies are technically possible but commercially harder to justify for a mature, low-cost drug unless they support a new route of administration, pediatric product, rapid-onset claim, or 505(b)(2) positioning.

A solubility-enhanced product can generate intellectual-property value through composition, process, particle-size, or dosage-form claims. It also creates greater manufacturing complexity and a higher regulatory burden.

What patents protect gefitinib formulations and when does exclusivity expire?

Gefitinib’s primary composition-of-matter patent protection is generally regarded as expired in major markets. The principal early U.S. patent family includes U.S. Patent No. 5,747,498, associated with AstraZeneca’s quinazoline EGFR inhibitor program. The effective expiry date depended on patent-term rules, adjustments, and jurisdictional treatment, but the core U.S. protection was not a durable barrier to modern generic development.

The relevant protection categories are now more likely to involve:

• Formulation patents.
• Particle-size or crystalline-form patents.
• Manufacturing processes.
• Combination therapies.
• Biomarker-selected methods of treatment.
• Pediatric or modified-release presentations.
• Regional patents outside the United States.

Protection category	Commercial relevance
Core compound patent	Largely expired in major markets
Original tablet formulation	Limited remaining barrier where patents have expired
Method-of-use claims	May remain relevant in selected jurisdictions
EGFR mutation testing	Diagnostic and regulatory issue, not a gefitinib excipient barrier
New formulation patents	Possible basis for 505(b)(2) or differentiated products
Manufacturing patents	Can restrict process copying but usually do not block all generic routes

An applicant must conduct a live patent and Orange Book review before filing. The FDA Orange Book identifies the reference NDA and listed patents, but listing status, patent expiry, pediatric extensions, and regulatory exclusivity can change. A generic applicant should not assume that historical patent expiry eliminates every litigation risk.

What is the Orange Book status of gefitinib?

Iressa is associated with U.S. NDA 021399. Gefitinib is an orally administered small molecule and is eligible for ANDA competition rather than biosimilar competition.

The practical Orange Book questions are:

• Whether any patent remains listed against NDA 021399.
• Whether a listed patent has an unexpired term.
• Whether the proposed generic label overlaps a method-of-use patent.
• Whether a Paragraph IV certification is required.
• Whether the reference product retains any pediatric or other statutory exclusivity.
• Whether the proposed product can use the full reference labeling.

For a standard 250 mg immediate-release generic, the principal regulatory route is an ANDA demonstrating pharmaceutical equivalence and bioequivalence. A 505(b)(2) application becomes more relevant when the sponsor changes the formulation, dosage form, route, strength, or labeling in a manner that cannot be supported through an ANDA.

When does gefitinib lose market exclusivity?

Gefitinib’s broad market exclusivity has already eroded in most major markets. The commercial market is primarily generic, although brand and branded-generic products remain important in countries where reimbursement, physician familiarity, or local distribution supports premium pricing.

Milestone	Date or status
Initial U.S. accelerated approval	2003
U.S. withdrawal from broad use	2011
U.S. mutation-directed reapproval	2015
Core composition protection	Generally expired in major markets
Generic competition	Established in many countries
Biosimilar competition	Not applicable
Current opportunity	Cost-efficient generic supply and differentiated formulations

The 2015 U.S. reapproval did not recreate broad composition-of-matter exclusivity. It restored a regulated market for a narrower, biomarker-selected population.

What Paragraph IV challenges and litigation risks affect gefitinib?

A Paragraph IV challenge is relevant only if an unexpired Orange Book-listed patent covers the reference product or its approved use. For an older product such as gefitinib, the most likely U.S. patent risks arise from later-listed formulation or method-of-use patents rather than the original compound patent.

Potential litigation theories include:

• Infringement based on a patented EGFR-mutation treatment method.
• Infringement based on a formulation or dosage regimen.
• Inducement based on the proposed prescribing information.
• Patent-term or pediatric-extension disputes.
• Product-by-process or polymorph claims in selected jurisdictions.

A generic applicant may reduce litigation exposure by using a label carve-out for patented methods, where legally permissible. A carve-out must not remove information necessary for the safe and effective use of the approved generic indication.

No biosimilar litigation framework applies because gefitinib is not a biologic. Competition is driven by ANDA litigation, national generic procedures, and ordinary patent enforcement.

What commercial opportunities exist for gefitinib excipients?

Low-cost global generic supply

The largest opportunity is operational rather than technological. A manufacturer can compete through:

• Stable API and excipient sourcing.
• Multi-country regulatory packages.
• High-throughput tableting.
• Robust dissolution across batches.
• Packaging that protects against moisture.
• Reliable supply to public-sector tenders.

A formulation using conventional excipients is suitable for high-volume manufacturing and contract development organizations.

Pediatric and dysphagia-friendly products

Gefitinib is used in oncology populations that may include patients with swallowing difficulties. Potential products include dispersible tablets, oral suspensions, oral powders, or smaller tablets.

These products may support a 505(b)(2) or non-U.S. hybrid strategy, depending on the jurisdiction. Excipient selection becomes more demanding because the sponsor must address taste, physical stability, dose uniformity, sedimentation, preservative systems, and compatibility with enteral feeding tubes.

Fixed-dose combinations

Potential combination concepts include gefitinib with supportive-care agents or other anticancer therapies. The strongest regulatory and commercial cases would require clinical justification and a clear dosing advantage. Combination products may create new patent opportunities but also increase development costs and regulatory complexity.

Reformulation for improved dissolution

A differentiated product could use nanocrystals, spray-dried dispersion, or a self-emulsifying system. The commercial case is strongest where the formulation improves administration, reduces variability, or enables a new dosage form. A simple dissolution improvement without clinical or handling benefit may not support premium pricing.

Excipient supply and co-processed platforms

Excipient manufacturers can target gefitinib and similar poorly soluble kinase inhibitors with:

• Co-processed direct-compression systems.
• Surfactant-containing granulation platforms.
• Low-moisture disintegrant systems.
• Taste-masking systems for liquid products.
• Film-coating systems with improved light and moisture protection.

A platform validated across multiple kinase inhibitors may have more value than a gefitinib-only product.

How does gefitinib compare with competing EGFR inhibitors?

Drug	Common dosage form	Formulation opportunity	Competitive position
Gefitinib	250 mg immediate-release tablet	Generic tablet, dispersible product, dissolution optimization	Mature and price-sensitive
Erlotinib	Immediate-release tablet	Solubility and food-effect management	Generic competition; different labeling
Afatinib	Immediate-release tablet	Conventional solid dose and patient-specific strengths	More complex toxicity and dosing profile
Osimertinib	Immediate-release tablet	Higher-value protected product and lifecycle management	Stronger current commercial position
Dacomitinib	Immediate-release tablet	Limited-volume specialty generic opportunity	Smaller market

Gefitinib has a lower development barrier than newer EGFR inhibitors because its reference formulation is conventional and its core patent estate is mature. Its principal disadvantage is lower pricing and intense generic competition.

How strong is the patent estate for a new gefitinib excipient formulation?

A new formulation can have moderate patent strength if it claims a technically specific and reproducible feature, such as:

• A defined particle-size distribution.
• A specific amorphous solid-dispersion composition.
• A narrow excipient ratio tied to dissolution performance.
• A stable liquid formulation.
• A tube-compatible or dispersible dosage form.
• A manufacturing process that produces a defined solid state.

Patent strength is weaker when claims merely recite broad excipient classes or conventional tablet ingredients. A formulation patent should be supported by comparative dissolution, stability, manufacturability, and, where relevant, pharmacokinetic data.

The strongest commercial position usually combines formulation claims with manufacturing know-how that is difficult to detect from the finished tablet.

What regulatory strategy is best for a gefitinib product?

For a standard 250 mg tablet, an ANDA is normally the most efficient U.S. route. The product should target pharmaceutical equivalence, bioequivalence, comparable dissolution, and an appropriate label.

A 505(b)(2) strategy is more appropriate for:

• A dispersible or liquid dosage form.
• A new route of administration.
• A clinically meaningful formulation change.
• A modified dosing regimen.
• A pediatric product.
• A combination product.

FDA bioequivalence planning should address the drug’s solubility behavior, dissolution method discrimination, fed and fasting conditions where applicable, and the impact of formulation changes. ICH M9 principles on biopharmaceutics classification and biowaivers may inform development, but sponsors must apply the current product-specific FDA requirements rather than relying on classification alone (International Council for Harmonisation, 2021).

What manufacturing and IP barriers exist?

Gefitinib does not present the same manufacturing complexity as a biologic or sterile injectable. The main barriers are formulation reproducibility and commercial scale.

Key manufacturing controls include:

• API particle-size distribution.
• Uniform surfactant distribution.
• Lubrication time and magnesium stearate level.
• Granulation endpoint, where wet granulation is used.
• Tablet hardness and friability.
• Disintegration time.
• Multi-point dissolution.
• Moisture exposure during coating and packaging.
• Coating weight gain and color uniformity.

Packaging may use high-barrier blister systems or bottles with desiccant, depending on stability data and regional requirements.

The IP barrier is generally lower for a conventional generic tablet and higher for a differentiated dosage form. Process patents, polymorph claims, and method-of-use patents should be screened separately from Orange Book-listed rights because national patent coverage may differ materially.

Key Takeaways

• Gefitinib is a mature small-molecule EGFR inhibitor with established generic competition.
• The reference product is a conventional 250 mg immediate-release film-coated tablet.
• Lactose, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, and magnesium stearate form the core excipient platform.
• pH-dependent solubility makes wetting, disintegration, lubrication, and dissolution control central to product performance.
• The lowest-risk opportunity is a Q1/Q2-aligned ANDA tablet.
• Higher-value opportunities include dispersible, liquid, pediatric, tube-compatible, or solubility-enhanced formulations.
• Gefitinib has no biosimilar pathway because it is a chemically synthesized small molecule.
• Core composition-of-matter protection is generally expired in major markets; residual risk is more likely to involve later formulation, method-of-use, or process claims.
• Commercial returns depend more on manufacturing cost, supply reliability, and geographic coverage than on premium pricing.
• New excipient technologies are most attractive when they create a clinically or operationally meaningful dosage-form advantage.

FAQs about gefitinib excipient and formulation opportunities

What is the best disintegrant for a gefitinib generic tablet?

Croscarmellose sodium is the closest reference-product choice. Crospovidone may be evaluated as an alternative, but the substitution should be supported by comparative dissolution and stability data.

Can gefitinib be formulated as an oral suspension?

Yes, but an oral suspension would require control of particle settling, dose uniformity, wetting, redispersibility, taste, preservative compatibility, and chemical stability. It would likely require a regulatory pathway beyond a standard ANDA.

Is sodium lauryl sulfate essential in gefitinib tablets?

It is not necessarily essential, but it can materially improve wetting and dissolution. Removing or reducing it may be feasible with API particle engineering or another surfactant system, subject to bioequivalence and dissolution results.

Does gefitinib require a biosimilar application?

No. Gefitinib is a synthetic small molecule. Generic applicants generally use an ANDA or the applicable national small-molecule generic pathway.

What is the most attractive commercial reformulation opportunity?

A dispersible or liquid product for patients with swallowing difficulties has a clearer product-use rationale than a tablet that only marginally improves dissolution. Its value depends on clinical need, regulatory exclusivity, reimbursement, and the ability to secure defensible formulation claims.

References

AstraZeneca. (2015). IRESSA (gefitinib) tablets, prescribing information. U.S. Food and Drug Administration.

International Council for Harmonisation. (2021). M9: Biopharmaceutics classification system-based biowaivers. ICH.

U.S. Food and Drug Administration. (2015). FDA approves Iressa for metastatic non-small cell lung cancer. FDA.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

U.S. Patent No. 5,747,498. (1998). Quinazoline derivatives. U.S. Patent and Trademark Office.